Irinotecan Accord

Irinotecan, the active ingredient in Irinotecan Accord, is a topoisomerase I inhibitor presented as an intravenous solution for intravenous use. It treats metastatic colorectal cancer and other solid tumors in adult patients and is administered under medical supervision in oncology settings.

GNH USA supplies Irinotecan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides reliable logistics for hospitals, pharmacies and clinical trial sites across multiple regions globally efficiently.

Irinotecan is employed in oncology to target cancers that depend on topoisomerase I activity. - Metastatic colorectal cancer: used in combination regimens to improve overall survival in adult patients. - Advanced gastric cancer: incorporated into selected multi‑drug protocols under specialist supervision. - Pancreatic cancer: considered as part of combination chemotherapy for eligible patients.

Irinotecan is associated with a range of adverse reactions that vary in frequency and severity. Common Side Effects: - Diarrhea: often severe and may require antidiarrheal therapy. - Neutropenia: reduced white blood cell count increasing infection risk. - Nausea and vomiting: may occur during or after infusion. - Fatigue: generalized tiredness reported by many patients. Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring urgent care. - Severe colitis: life‑threatening inflammation of the colon. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis.

When using Irinotecan, clinicians should observe specific safety measures to minimize risks. - Monitor blood counts: perform regular complete blood count tests to detect neutropenia early. - Assess liver function: evaluate hepatic enzymes before each cycle as metabolism depends on liver activity. - Adjust for renal impairment: consider dose modification in patients with reduced kidney function. - Avoid in known hypersensitivity: discontinue if allergic reactions such as rash or bronchospasm occur. - Pregnancy and breastfeeding: use only if potential benefit justifies potential risk, as safety data are limited. - Store at ambient temperature: keep the solution in the original container, protect from light and moisture.

Irinotecan may interact with other medicines, altering its efficacy or toxicity. Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): can lower SN‑38 concentrations and reduce efficacy. - UGT1A1 inhibitors (e.g., atazanavir): raise SN‑38 levels, increasing risk of severe toxicity. - Concurrent myelosuppressive chemotherapy: may intensify neutropenia and thrombocytopenia. Moderate Interactions (Monitor Closely): - Warfarin: may alter INR, necessitating closer coagulation monitoring. - Fluoropyrimidines (e.g., 5‑FU): combined use can heighten hematologic adverse effects.